We are continually pushing the boundaries of science and technology to enable early, actionable, and personalized diagnoses in our mission to improve and save lives. Our cutting-edge technologies are powering the discovery of new biology and accurate biomarkers that address scientific knowledge gaps and clinical unmet needs.
MiRXES was founded to commercialize our industry-leading ID3EAL reverse transcription quantitative polymerase chain reaction (RT-qPCR) platform for detection of microRNAs and other non-coding RNAs. This technology powers our flagship GASTROClear gastric cancer early detection test and is the foundation on which our multi-cancer early detection clinical pipeline is built.
Our technology is available for research use through our comprehensive range of Biopharma and Life Science discovery tools and services. We also collaborate extensively with clinical, academic, and industry partners on diagnostic applications in various disease areas, including cancer, cardiovascular diseases, metabolic diseases, and infectious diseases.
We are also developing and aggregating new technologies for RNA-centric multi-omics diagnostics, to provide physicians and patients a more complete snapshot of disease biology and to enable early disease interception.
Conformation-restricted microRNA-specific RT primer that efficiently hybridizes to mature target microRNA
microRNA-specific forward and reverse real-time PCR primers confer further specificity to enable robust
Optimized RT and qPCR master mixes enhance the signal-to-noise ratio